<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD"><gtr:id>B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD</gtr:id><gtr:name>Great Western Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A88086FE-C28F-4863-8B2B-1A97734A6C79"><gtr:id>A88086FE-C28F-4863-8B2B-1A97734A6C79</gtr:id><gtr:name>University of Strasbourg</gtr:name><gtr:address><gtr:line1>Universite Louis Pasteur</gtr:line1><gtr:line2>4 rue Blaise Pascal</gtr:line2><gtr:line4>Strasbourg</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>67070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0DE10BF6-639D-43F2-8A56-04B727EC99C5"><gtr:id>0DE10BF6-639D-43F2-8A56-04B727EC99C5</gtr:id><gtr:name>University of Stavanger</gtr:name><gtr:address><gtr:line1>University of Stavanger</gtr:line1><gtr:postCode>N-4036</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1FADA516-503F-4D04-96FD-28248BF7B77E"><gtr:id>1FADA516-503F-4D04-96FD-28248BF7B77E</gtr:id><gtr:name>The Binding Site</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF390CF0-ECD3-47D8-B9A8-7602AF319BEE"><gtr:id>EF390CF0-ECD3-47D8-B9A8-7602AF319BEE</gtr:id><gtr:name>Northumbria University</gtr:name><gtr:address><gtr:line1>Ellison Place</gtr:line1><gtr:line4>Newcastle upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 8ST</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD"><gtr:id>B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD</gtr:id><gtr:name>Great Western Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A88086FE-C28F-4863-8B2B-1A97734A6C79"><gtr:id>A88086FE-C28F-4863-8B2B-1A97734A6C79</gtr:id><gtr:name>University of Strasbourg</gtr:name><gtr:address><gtr:line1>Universite Louis Pasteur</gtr:line1><gtr:line2>4 rue Blaise Pascal</gtr:line2><gtr:line4>Strasbourg</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>67070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0DE10BF6-639D-43F2-8A56-04B727EC99C5"><gtr:id>0DE10BF6-639D-43F2-8A56-04B727EC99C5</gtr:id><gtr:name>University of Stavanger</gtr:name><gtr:address><gtr:line1>University of Stavanger</gtr:line1><gtr:postCode>N-4036</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1FADA516-503F-4D04-96FD-28248BF7B77E"><gtr:id>1FADA516-503F-4D04-96FD-28248BF7B77E</gtr:id><gtr:name>The Binding Site</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF390CF0-ECD3-47D8-B9A8-7602AF319BEE"><gtr:id>EF390CF0-ECD3-47D8-B9A8-7602AF319BEE</gtr:id><gtr:name>Northumbria University</gtr:name><gtr:address><gtr:line1>Ellison Place</gtr:line1><gtr:line4>Newcastle upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 8ST</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AE7EA01F-0FBC-454A-9BBC-762E455AC90B"><gtr:id>AE7EA01F-0FBC-454A-9BBC-762E455AC90B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Emrys</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0FE65966-B767-48FA-B116-FA6215A648B7"><gtr:id>0FE65966-B767-48FA-B116-FA6215A648B7</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:otherNames>Stevenson</gtr:otherNames><gtr:surname>Gillespie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DFF758C5-064B-4650-8CA2-94D1953CB6A7"><gtr:id>DFF758C5-064B-4650-8CA2-94D1953CB6A7</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Bowman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/05727931-219D-4A7E-B86A-68B467362B5B"><gtr:id>05727931-219D-4A7E-B86A-68B467362B5B</gtr:id><gtr:firstName>Jennifer</gtr:firstName><gtr:otherNames>Susan</gtr:otherNames><gtr:surname>Hallinan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A3DD2ABC-D15C-49BC-80DE-AE40EF521AA5"><gtr:id>A3DD2ABC-D15C-49BC-80DE-AE40EF521AA5</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:otherNames>Christopher</gtr:otherNames><gtr:surname>Swan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8337C44-7C9D-4E5C-9D4B-EC284605F8E2"><gtr:id>B8337C44-7C9D-4E5C-9D4B-EC284605F8E2</gtr:id><gtr:firstName>Wan-Fai</gtr:firstName><gtr:surname>Ng</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/55E15710-D860-4AB7-833A-41F0F7440C5B"><gtr:id>55E15710-D860-4AB7-833A-41F0F7440C5B</gtr:id><gtr:firstName>Elizabeth Jayne</gtr:firstName><gtr:surname>Price</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA849CDB-222D-427A-A134-3338D1EF5043"><gtr:id>DA849CDB-222D-427A-A134-3338D1EF5043</gtr:id><gtr:firstName>Anil</gtr:firstName><gtr:surname>Wipat</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/57A37958-62F0-4123-94F1-B401A3343848"><gtr:id>57A37958-62F0-4123-94F1-B401A3343848</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Dudley</gtr:otherNames><gtr:surname>Isaacs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/59B366E2-4FA1-4239-94A4-E9FC3B9D24EA"><gtr:id>59B366E2-4FA1-4239-94A4-E9FC3B9D24EA</gtr:id><gtr:firstName>Julia</gtr:firstName><gtr:surname>Newton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ002720%2F1"><gtr:id>0638DC02-7EE3-458E-A39E-5AACEE2A8DE6</gtr:id><gtr:title>Identifying the biological fingerprints of fatigue</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J002720/1</gtr:grantReference><gtr:abstractText>Context of the research:
Chronic fatigue syndrome (CFS) affects 1 in 300 people in the UK and is associated with a significant healthcare-related cost to the society. Severe, persistent fatigue is a key symptom of CFS and a major factor leading to loss of productivity in this illness. The cause of CFS and the underlying biological mechanisms of fatigue are poorly understood. As a result, accurate diagnosis of CFS can be difficult and effective treatment is not available. A growing body of evidence suggests that CFS may be linked to a faulty immune system. However, in what ways the immune system is not working properly is not clear. Therefore, by uncovering the abnormalities of the immune system in CFS in detail, it will help make the diagnosis of CFS easier and more accurate as well as give us clues to develop effective treatment of this condition.

Since the diagnosis of CFS is unreliable at present, a group of &amp;quot;CFS&amp;quot; patients may in fact consist of individuals with different diseases. This presents a major obstacle to the progress of CFS research and may also explain why data from different CFS research studies are often conflicting. Therefore, in order to better understand the underlying biological mechanisms of CFS, a different approach is needed. Recent data show that intense fatigue is also a common symptom for many chronic conditions. Interestingly, most of these conditions are due to a faulty immune system. Furthermore, research also suggests that severe fatigue in these various conditions is driven by similar biological mechanisms. If so, we may be able to find out the underlying defects of the immune system causing disabling fatigue in CFS by using one of these chronic conditions as a disease model. This is precisely what we will do in this study. 

We will carry out a comprehensive analysis of the immune system of a large number of patients with a condition called primary Sj&amp;ouml;gren syndrome (PSS). We will analyze the data obtained from these experiments to ind out what abnormalities of the immune system are linked to fatigue. Since these experiments typically produce a vast amount of data, we will apply statistical methods and mathematical modelling specifically designed to analyse large volumes of biological data (known as bioinformatics and biostatistics) in order to identify the biological &amp;quot;fingerprints&amp;quot; of fatigue. We will then test whether these biological fingerprints of fatigue are present in CFS patients and whether it will help us to diagnose CFS more accurately.

We chose PSS as a disease model for several reasons. (i) PSS and CFS have many shared clinical and biological features including profound fatigue. (ii) Clinical samples from over 550 PSS patients across the UK, as well as their clinical data, are available for this study. Access to such samples is a distinct advantage because this is one of the largest clinical sample collections in PSS in the world. It would be time-consuming, labour-intensive and expensive if we had needed to collect the same amount of clinical samples and accompanied clinical data from fresh. (iii) There are well-established diagnostic criteria for PSS and so this avoids the problem of studying patients with potentially mixed diagnoses as in the case of studying CFS patients. 

Aims of the study, potential applications and benefits:
The main objective of this study is to find the biological fingerprints of fatigue. By doing so, it will improve our understanding of the biological mechanisms of fatigue. The data will enable us to develop treatments for the fatigue that plagues so many patients with CFS and other chronic conditions. It will also help us to design a clinical test for the diagnosis of CFS.</gtr:abstractText><gtr:technicalSummary>This study aims to identify the biological fingerprints of fatigue using primary Sjogren's syndrome (PSS), an autoimmune condition with several clinical and biological features similar to chronic fatigue syndrome (CFS) including intense fatigue, as a disease model. We will then test whether these biological fingerprints are also present in patients with CFS. 

We will perform whole blood gene expression profiling (using genome-wide microarray) and measure serum markers of immune dysregulation (using fluorescent bead-based multiplex technology) of an existing biobanked samples from a large cohort of clinically well-characterized PSS patients (the UK PSS registry). Further information concerning the cohort can be found on the cohort website www.sjogrensregistry.org and Annex 1. The data from these experiments will be analyzed using various bioinformatics techniques in order to identify a biological profile of fatigue, which will be validated using a second blinded test cohort of PSS patients. We will also investigate whether the biological profile changes over time and responds to biological treatment of fatigue in PSS patients. The data from these investigations will then be integrated to identify a set of biomarkers that will maximally discriminate fatigued subjects from non-fatigued individuals. Finally, we will test whether these biomarkers of fatigue are present in CFS patients and if so, whether they can be used to correctly classify CFS from active or sedentary healthy individuals.</gtr:technicalSummary><gtr:potentialImpactText>Chronic fatigue is a global health problem. Severe, debilitating fatigue is not only the cardinal symptom of chronic fatigue syndrome (CFS), but also a common problem in many chronic diseases, cancers and a side-effect of many treatments such as cytokine-based therapies and chemotherapies. In the wider health-economic context, chronic fatigue is a common complaint in primary care settings and is a major cause of productivity loss at work places and associated poor quality of life. It places a considerable burden on the NHS. It has been estimated to cost over &amp;pound;633 millions every year in a survey carried out in 2000. In the US, a study in 2009 estimated an annual loss of over US$136 billion in productivity.

Despite being a common symptom, fatigue is a poorly understood phenomenon and the treatment of fatigue is largely ineffective. In addition, adequate assessment of a complex, multi-faceted symptom such as fatigue remains a challenge to researchers and clinicians alike.

Therefore, by seeking the biological fingerprints of fatigue using a hypothesis-free approach, the data generated from this study will have a substantial scientific and societal impact. In the short term, it will address a key knowledge gap in the biological mechanisms of fatigue and CFS as well as inform future directions of research in these areas. The development of a recognized biomarker would ease the stigma sometimes associates with CFS/ME through the lack of such a diagnostic.

In the longer term, the biomarkers of fatigue identified in this proposal can be used to study chronic fatigue in other conditions. These biomarkers may also facilitate the development of targeted therapies, provide an objective assessment of responses to treatments in clinical trials and improve our diagnosis and stratification of fatigue and CFS. The development of any drugs or therapies would be of potential benefit to pharmaceutical companies and the economy.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>451572</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Binding Site</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Research collaboration</gtr:description><gtr:id>41AA1F43-FF16-497D-9459-2B0005182F6F</gtr:id><gtr:impact>Analysis complete, preparing manuscript for publication</gtr:impact><gtr:outcomeId>CbuhWf29LWc-1</gtr:outcomeId><gtr:partnerContribution>Analyse the samples for the agreed analytes of interest and provide support in data analysis. All raw data generated will be returned to the UKPSSR for storage and future use</gtr:partnerContribution><gtr:piContribution>Provide biobanked serum sample and anonymised clinical data for the research project</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Ageing and Health</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>61CF3E89-7801-4BAD-8D70-0DB71C239A8F</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-5</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Cell and Molecular Biosciences</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>0D8CC9DD-3D20-449A-B4DD-E30C86CC515D</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-4</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Computing Science</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>E2FEAF45-BF9E-4C37-8931-8CED8C22DD14</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-3</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Research Collaboration - Interferon signature in PSS</gtr:description><gtr:id>0C458D2E-9794-44D5-9304-47305F929E8D</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>545a24d04fae48.67749681-1</gtr:outcomeId><gtr:partnerContribution>Conducting experiments</gtr:partnerContribution><gtr:piContribution>Providing samples for research and contribute to research design, data analysis and interpretation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northumbria University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of a user-informed invention to improve the function of primary Sjogren's syndrome patients</gtr:description><gtr:id>2DAAE041-1C7E-4B0C-93F8-BF8147FF8BC3</gtr:id><gtr:impact>Partnership has only just started</gtr:impact><gtr:outcomeId>ZGYpR8DosEz-1</gtr:outcomeId><gtr:partnerContribution>Assistance in data analysis and non-pharmacologica aspect of intervention development</gtr:partnerContribution><gtr:piContribution>provide intellectual input on study design, using UKPSSR data for inviting partient to participating in this study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Strasbourg</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Research collaboration - validation</gtr:description><gtr:id>5BAEDE7C-5CE6-4381-8CAB-470F5DF72A1E</gtr:id><gtr:impact>Oral presentation at American College of Rheumatology Annual Conference and Won the best abstract prize in Sjogren's syndrome</gtr:impact><gtr:outcomeId>58b1be693dcfb9.95604712-1</gtr:outcomeId><gtr:partnerContribution>Provide anonymised data for validation</gtr:partnerContribution><gtr:piContribution>Generate original data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rheumatology University Hospitals Birmingham</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>FDCE2514-E5FB-4D4D-AB82-D5501E1146B2</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-1</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Western Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rheumatology Department Great Western Hospitals</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>AA983477-C071-42A4-B597-411EA9A272EC</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-2</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stavanger</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Research collaboration - validation</gtr:description><gtr:id>47EC44F5-3579-463A-ABE2-0125CC2CB3CA</gtr:id><gtr:impact>Oral presentation at American College of Rheumatology Annual Conference and Won the best abstract prize in Sjogren's syndrome</gtr:impact><gtr:outcomeId>58b1be693dcfb9.95604712-2</gtr:outcomeId><gtr:partnerContribution>Provide anonymised data for validation</gtr:partnerContribution><gtr:piContribution>Generate original data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stavanger</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Immunology</gtr:department><gtr:description>Research Grant application</gtr:description><gtr:id>8C9DCD05-7329-4797-AF46-9BA94B389A54</gtr:id><gtr:impact>Awaiting outcome of the application</gtr:impact><gtr:outcomeId>TnEDF5WVVqm-1</gtr:outcomeId><gtr:partnerContribution>Conduct the experiments described in the grant application</gtr:partnerContribution><gtr:piContribution>Provide biobanked DNA and serum samples for the research project, if the application to the Norwegian Research Council is successful</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk (CFS/ME collaborative, Bristol, 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>75544CB5-1ACA-46F7-BA88-E8604325061A</gtr:id><gtr:impact>Raising interest in the area of my research

Dissemination of research idea and data</gtr:impact><gtr:outcomeId>545a7451d1ac63.35156540</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR annual meeting (Rome, 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>24A01390-0948-4A8E-8601-912D5EFA277D</gtr:id><gtr:impact>I give a plenary talk on the current research in primary Sjogren's syndrome at the conference</gtr:impact><gtr:outcomeId>56d1bf1004fb82.43979271</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Proximity to Discovery themed week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>395CA2F1-899B-499C-B403-FD7097B62620</gtr:id><gtr:impact>This is a week of engagement activity targeting senior members of pharmaceutical/biotechnology industry to promote collaboration.
representatives from 5 pharmaceutical companies and a biotech company attended the meeting.
All companies showed great interest in our research into Sjogren's and fatigue.</gtr:impact><gtr:outcomeId>56d1c614ea9742.49511718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (BSR annual conference, 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>22C3E589-42BF-4CDA-A28C-C9DC23CC589D</gtr:id><gtr:impact>Improve the profile of fatigue research

New collaborative research being established</gtr:impact><gtr:outcomeId>545a7560844a47.64337902</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Translational research partnership with several pharmaceutical companies to develop/test novel therapeutic targets for primary Sjogren's syndrome</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8A260B6C-AABB-4F1B-A1E3-94FD903391C1</gtr:id><gtr:impact>Consultation agreements, collaborative research activities

Facilitate development of novel therapies for primary Sjogren's syndrome</gtr:impact><gtr:outcomeId>eCVTwEgTUaR</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific Advisory Board</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7E2538F0-B867-4D8F-A109-BF4BCBA5A419</gtr:id><gtr:impact>I have served on scientific advisory board for several pharmaceutical companies planning early phase clinical trials in Sjogren's syndrome and in fatigue.</gtr:impact><gtr:outcomeId>56d1cf40129cf5.88836038</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20018</gtr:fundingRef><gtr:id>858FC501-D394-445A-ADDE-B893ACFE629A</gtr:id><gtr:outcomeId>56d1b872b976a5.94776533</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45332</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK Education Grant</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>44A51CFB-005C-4BF7-A979-A099F06FCA07</gtr:id><gtr:outcomeId>545a1e5f36c826.91217484</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>280000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Horizon2020</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>093D2B6D-8420-440E-A63A-AD347C558CC6</gtr:id><gtr:outcomeId>58b1c54faa62f7.08349745</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52884</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>The JGW Patterson Foundation</gtr:fundingOrg><gtr:id>2B9D4297-10F8-41EA-B7E9-CD9985687A41</gtr:id><gtr:outcomeId>58b1c5e8969b01.31638643</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proximity to Discovery</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>ECC41CD5-E6A6-4B7A-8890-769540A107B4</gtr:id><gtr:outcomeId>56d1ba734e9b80.43770344</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>159609</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK project grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>21183</gtr:fundingRef><gtr:id>D5B0DF4E-3A61-43E5-BDE2-6ACA0554962A</gtr:id><gtr:outcomeId>56d1b6d26d1d40.23509751</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK project grant</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>21183</gtr:fundingRef><gtr:id>4844256C-0335-47C5-AE80-097B36C76DC2</gtr:id><gtr:outcomeId>58b1c05c2e9064.68844373</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>177122</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Training Fellowship</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20169</gtr:fundingRef><gtr:id>216D3AD8-7722-45EF-8AE3-8B32960A3ADD</gtr:id><gtr:outcomeId>iT2QAd2xZ8Q</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Committee member of the BSR Management Guideline development group for primary Sjogren's syndrome</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0EF735CA-D605-41D6-9A3C-09E1C469D38F</gtr:id><gtr:outcomeId>56d1c297d28054.13096941</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to join the Outcome Measures Online Training Advisory Committee</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D99A2D34-452D-4EB0-96BD-1E31224DE8BA</gtr:id><gtr:outcomeId>58bd4ed65795e0.62767683</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to join the Sjogren's Syndrome Foundation Clinical Trial Consortium (US)</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>EA179A8C-CE87-452C-AFA6-79AB2994D20D</gtr:id><gtr:outcomeId>58bd4e51d0e3b9.68662621</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Collection of &amp;gt;750 clinically well-characterised patients with associated biobanked samples</gtr:description><gtr:id>34F45009-CBF9-406D-BEFD-8AFDB87249D5</gtr:id><gtr:impact>By 2014, it has led to 15 peer-reviewed publications, leveraged additional research funding and many new research collaborations.</gtr:impact><gtr:outcomeId>545a26cebc1cf7.92992263</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK primary Sjogren's syndrome registry</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.sjogrensregistry.org</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Using the biological samples from the UKPSSR, we have now generated data on whole genome expression analyses of whole blood samples from over 300 PSS patients and around 50+ healthy controls.</gtr:description><gtr:id>260178EE-942A-4148-B2E1-A8D0AEB8D714</gtr:id><gtr:impact>The data were generated in two phases. The data from phase 1 have been published and deposited in the GEO database which is accessible to the public (accession number GSE66795)
The phase 2 data are currently being used for our own study and in another study in collaboration with a research group in France. We are expecting to publish the data in the near future.</gtr:impact><gtr:outcomeId>58bd5334eee801.46437138</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A large genowide expression datasets</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Serum, DNA, RNA, PBMC</gtr:description><gtr:id>F6123EA1-4747-49CB-8E8F-23DAEC1E87A4</gtr:id><gtr:impact>Serum samples were sent to Liverpool University for the study of a novel autoantibody in primary Sjogren's syndrome - study ongoing
DNA samples were sent to Oklahoma Medical Research Foundation for a genome-wide association study in primary Sjogren's syndrome. Various other biological samples have subsequently been sent to several other collaborative partners including industrial partners. It has led to 15 peer-reviewed publication, additional grant funding, some of the studies are ongoing</gtr:impact><gtr:outcomeId>ZpH76NisREV</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UKPSSR biological materials</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>192A087D-EBDD-4502-80F7-610383F87D17</gtr:id><gtr:title>Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/124abeb653e0da8651b79d350bd9d868"><gtr:id>124abeb653e0da8651b79d350bd9d868</gtr:id><gtr:otherNames>Lessard CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_12951_21_24097067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCE430E6-057B-48B4-BF02-1C8942F9BEBE</gtr:id><gtr:title>Association of genes in the NF-?B pathway with antibody-positive primary Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2948d4313594ee88110ed29a5b5a57a2"><gtr:id>2948d4313594ee88110ed29a5b5a57a2</gtr:id><gtr:otherNames>Nordmark G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-9475</gtr:issn><gtr:outcomeId>pm_12951_21_23944604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C561196-108C-4036-A6DA-63295F9C8400</gtr:id><gtr:title>Developing a service user informed intervention to improve participation and ability to perform daily activities in primary Sj&amp;ouml;gren's syndrome: a mixed-methods study protocol.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b26f74ea8e57a53372c736edae9acdd"><gtr:id>2b26f74ea8e57a53372c736edae9acdd</gtr:id><gtr:otherNames>Hackett KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5458a0b2a90fe3.03586402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F01DECC-6657-4854-B7BA-D0B6F39020FE</gtr:id><gtr:title>A Transcriptional Signature of Fatigue Derived from Patients with Primary Sj&amp;ouml;gren's Syndrome.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/693b1e1e986b283a9b0feff1c8de8f12"><gtr:id>693b1e1e986b283a9b0feff1c8de8f12</gtr:id><gtr:otherNames>James K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d1b41c5c5da1.54096854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>482D253A-BBC8-49C3-84CA-F82D414D0FF2</gtr:id><gtr:title>Systemic interferon type I and type II signatures in primary Sj&amp;ouml;gren's syndrome reveal differences in biological disease activity.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0886adc65ce3295f7aa02b5cba8349f"><gtr:id>e0886adc65ce3295f7aa02b5cba8349f</gtr:id><gtr:otherNames>Bodewes ILA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a96c221ddb8e7.68368593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E190F715-9AC4-4074-B7F9-337C6353F043</gtr:id><gtr:title>Fatigue in primary Sj&amp;ouml;gren's syndrome is associated with lower levels of proinflammatory cytokines.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bb89d49892919f3cb1bc3847823c40f"><gtr:id>6bb89d49892919f3cb1bc3847823c40f</gtr:id><gtr:otherNames>Howard Tripp N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>58514f4b6088b2.42429642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D52D32FC-1BC7-47E1-BFD9-DED96DE39236</gtr:id><gtr:title>Clinically proven mtDNA mutations are not common in those with chronic fatigue syndrome.</gtr:title><gtr:parentPublicationTitle>BMC medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/742eb8a5ad4f031cd2f66c982ba3692e"><gtr:id>742eb8a5ad4f031cd2f66c982ba3692e</gtr:id><gtr:otherNames>Schoeman EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2350</gtr:issn><gtr:outcomeId>5a10c385485d25.85563441</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J002720/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>986F1CAE-CC43-4D59-8F85-A91971E4C4BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Other</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>